Jon Feingersh Photography Inc/DigitalVision via Getty Images Data reported earlier Monday from Viking Therapeutics ( NASDAQ: VKTX ) on its weight loss medicine VK2735 indicates that Novo Nordisk ( NVO ) and Eli Lilly ( NYSE: LLY ), which currently dominate the obesity drug space, could face competition. VK2735, which is being developed in both as.
Back to Health Page
